<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308348">
  <stage>Registered</stage>
  <submitdate>9/08/2009</submitdate>
  <approvaldate>20/08/2009</approvaldate>
  <actrnumber>ACTRN12609000716268</actrnumber>
  <trial_identification>
    <studytitle>Effect of intracameral Bevacizumab injection on corneal endothelial cells: an in vivo evaluation</studytitle>
    <scientifictitle>Effect of intracameral Bevacizumab injection on corneal endothelial cells in patients with iris neovascularization: an in vivo evaluation</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Corneal endothelial toxicity</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single injection of intracameral Bevacizumab at a concentration of 1.25 mg/0.05 mL for the treatment of iris neovascularization</interventions>
    <comparator>Two sessions of Pan retinal laser photocoagulation. Each comprising 500-700 shots over 15 minutes.one session each week for two weeks</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>endothelial cell density.The Noncon Robo Pachy Model SP-9000LC specular microscope (Konan Medical Corporation, Miyanishi-cho, Nishinomiya, Hyogo, Japan) was used to record the central corneal endothelial image and measures the corneal thickness. A KSS-300 Image Storage System (Konan Medical Corporation, Miyanishi-cho, Nishinomiya, Hyogo, Japan) was used to capture and save the image from the Noncon Robo specular microscope. The KSS-300 Image Storage System was later used to analyze the corneal endothelial image, using the centre method after counting a minimum of 10 cells in each eye.</outcome>
      <timepoint>4 weeks post treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>endothelial cell morphology.The Noncon Robo Pachy Model SP-9000LC specular microscope (Konan Medical Corporation, Miyanishi-cho, Nishinomiya, Hyogo, Japan) was used to record the central corneal endothelial image and measures the corneal thickness. A KSS-300 Image Storage System (Konan Medical Corporation, Miyanishi-cho, Nishinomiya, Hyogo, Japan) was used to capture and save the image from the Noncon Robo specular microscope. The KSS-300 Image Storage System was later used to analyze the corneal endothelial image, using the centre method after counting a minimum of 10 cells in each eye.</outcome>
      <timepoint>4 weeks post treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>regression of iris neovascularization will be assessed by performing anterior segment flourescein angiography before injection and 4 weeks after the injection and comparing them</outcome>
      <timepoint>4 weeks post treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients with iris neovascularization</inclusivecriteria>
    <inclusiveminage>38</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>corneal edema or preoperative corneal endothelial desnity&lt;1500 cells/mm2</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/12/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Cairo University Hospital</primarysponsorname>
    <primarysponsoraddress>84 shehab street
Mohandeseen
Giza 12411</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Cairo University Hospital</fundingname>
      <fundingaddress>84 shehab street
Mohandeseen
Giza
12411</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to evaluate the effect of a drug that decreases the growth of immature blood vessels that cause complications in the eye due to some diseases like diabetes. Its effect has been studied on the deep layers of the eye when injected in front of the retina, but this study evaluates its potential toxicity on the front side of the eye when injected just behind the cornea.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of Cairo University Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/11/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>19/10/2008</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>mohamed Hosny</name>
      <address>84 shehab street
Mohandeseen
Giza,12411</address>
      <phone>0020122112617</phone>
      <fax />
      <email>mohamedhosny@mac.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Mohamed Hosny</name>
      <address>84 Shehab street
Mohandeseen
Giza
12411</address>
      <phone>0020122112617</phone>
      <fax />
      <email>mohamedhosny@mac.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>